Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2)
Obesity · 2025
DOI: 10.1002/oby.24184 ↗At a glance
Journal article in Obesity, 2025. Written by Sean Wharton and 12 co-authors. Institution: McMaster University, Hamilton, Ontario and University of Toronto, Toronto, Ontario, Canada. Major MEDLINE topics: Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, Obesity, Randomized Controlled Trials as Topic. Cited 41 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIDDK NIH HHS, NCATS NIH HHS, Boehringer Ingelheim.
Abstract (original language)
Objective
The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon‐like peptide‐1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE‐1 and ‐2).
Methods
In these ongoing double‐blind trials, participants were randomized to once‐weekly subcutaneous injections of survodutide or placebo added to lifestyle modification. Survodutide doses are uptitrated to 3.6 or 6.0 mg, and dose flexibility is permitted.
Participants
( n = 726) in SYNCHRONIZE‐1 (NCT06066515) have a baseline BMI ≥ 30 kg/m 2 or ≥27 kg/m 2 with at least one obesity‐related complication but without T2D; participants ( n = 755) in SYNCHRONIZE‐2 (NCT06066528) have a baseline BMI ≥ 27 kg/m 2 and T2D. The primary endpoints are percentage change in body weight and proportion of participants achieving ≥5% body weight reduction from baseline to week 76. Secondary endpoints include change in systolic blood pressure and measures of glycemia. A SYNCHRONIZE‐1 substudy is evaluating changes in body composition and liver fat content using magnetic resonance imaging.
Conclusions
These trials are designed to provide robust evaluation of the efficacy, safety, and tolerability of survodutide for the treatment of obesity in the presence or absence of T2D.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- McMaster University, Hamilton, Ontario and University of Toronto, Toronto, Ontario, Canada.
- St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland.
- Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA.
- Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany.
- First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
ORCID profiles: Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, Elke Platz, Martina Brueckmann, Ania M Jastreboff, Sue D Pedersen, Lee M Kaplan
Funding
- NIDDK NIH HHS
- NCATS NIH HHS
- Boehringer Ingelheim
- Boehringer Ingelheim Stiftung
Cite
APA
Wharton, S., le Roux, C. W., Kosiborod, M. N., Platz, E., Brueckmann, M., Jastreboff, A. M., Ajaz Hussain, S., Pedersen, S. D., Borowska, L., Unseld, A., Kloer, I. M., Kaplan, L. M., & SYNCHRONIZE‐1 and ‐2 trial committees and investigators (2025). Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2). Obesity. https://doi.org/10.1002/oby.24184
Vancouver
Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2). Obesity. 2025. doi:10.1002/oby.24184
BibTeX
@article{Wharton2025,
author = {Wharton, Sean and le Roux, Carel W and Kosiborod, Mikhail N and Platz, Elke and Brueckmann, Martina and Jastreboff, Ania M and Ajaz Hussain, Samina and Pedersen, Sue D and Borowska, Luiza and Unseld, Anna and Kloer, Isabel M and Kaplan, Lee M and SYNCHRONIZE‐1 and ‐2 trial committees and investigators, SYNCHRONIZE‐1 and ‐2 trial committees and investigators},
title = {Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2)},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24184}
}
EUVIMED